Haier vs. 'Medical Beauty Queen': The Dark Side of Anti-Aging Clinics

A bitter public dispute between Chinese appliance giant Haier and controversial medical aesthetics entrepreneur Yu Wenhong has thrown a spotlight on the murky world of high-end anti-aging clinics. At the heart of the conflict is a Chengdu hospital offering "blood exchange" therapies that promise to reverse aging—treatments that lack scientific evidence and have been banned by regulators in the U.S. This isn't just a legal spat; it's a window into the aggressive marketing, questionable partnerships, and regulatory loopholes that plague China's rapidly growing medical aesthetics sector.

The dispute began on March 30 when Haier's financial arm issued a statement denying any affiliation with Yu Wenhong's Yumeiren Group and condemning her alleged claims about "extracting young people's blood" for anti-aging purposes. Yu responded by suing Haier for defamation, demanding a symbolic 1 yuan in damages and a public apology. She asserts that her company had legitimate business cooperation with Haier-backed medical institutions. The real story, however, lies in the complex ownership and operational structure of the clinic at the center of the controversy—Chengdu Xunshang Pengruili Hospital, which is partially owned by Haier and operated by a company linked to a convicted fugitive.

Key Facts

• The hospital's ownership is a tangled web. Chengdu Xunshang Pengruili Hospital is owned by a mix of investors: Singapore's Perennial Holdings (40%), the "Xunshang Group" (36%), and Haier (24%). The Xunshang Group, which operates the hospital, is led by Li Dale, a man with a criminal past.
• Li Dale, also known as Li Liang, is a convicted criminal. He was arrested in Hong Kong in 2015 for using forged documents, fled bail, and was recaptured in 2018, only to escape from a hospital by dismantling the ceiling. He was sentenced to prison in 2019. He later changed his name and rebranded himself as a Cambridge-educated medical entrepreneur.
• The hospital offers unproven "blood exchange" therapies. These include "blood purification" (priced at 198,000 yuan per session) and "young protein" infusions (49,800 yuan per group, typically sold in pairs), which claim to extract functional proteins from the blood of young people and inject them into older clients to reverse aging.
• Yu Wenhong promotes extreme anti-aging treatments. She has marketed an "endocrine axis" project that allegedly restores menstruation in postmenopausal women and enables fertility in women over 60, priced at 398,000 yuan. She also promotes a "Dubai peptide therapy" for super-wealthy clients, with prices exceeding 100 million yuan.
• The hospital avoids direct marketing of these services. While front-desk staff have admitted to offering plasma exchange for "rejuvenation," the hospital publicly distances itself from Yu's claims, even prohibiting partners from using Haier's or Perennial's names in promotional activities.
• Yu and Li have deep business ties. They co-founded a company called Forever Young (Hainan) Health Industry, which is linked to offshore entities in Hong Kong and the Cayman Islands, indicating a sophisticated corporate structure designed to obscure ownership.
• The hospital's business model relies on beauty salons. It partners with beauty chains like Nairui and Xiuyu to funnel customers into high-ticket medical procedures, a common practice in China's "channel medical aesthetics" industry.
• No scientific evidence supports these treatments. The U.S. FDA has explicitly warned that plasma infusions have no proven anti-aging benefits and carry risks of infectious diseases. Silicon Valley billionaire Bryan Johnson, who experimented with young blood transfusions, publicly admitted they were useless.

In-Depth Analysis

This dispute is more than a clash between a corporate giant and a flamboyant entrepreneur; it exposes the systemic failures in China's regulation of the medical aesthetics and anti-aging industry. The fact that a hospital with major corporate investors—including a Fortune Global 500 company like Haier and the family behind the famous cooking oil brand Arowana—can host medically dubious procedures under its roof highlights a critical gap in oversight. The hospital's strategy of maintaining plausible deniability, by not directly marketing the controversial treatments while allowing affiliated entities to do so, is a classic regulatory dodge. This case also reveals the growing trend of "channel medical aesthetics," where beauty salons act as middlemen, earning hefty commissions (up to 40%) for referring clients to medical procedures. This model incentivizes aggressive sales tactics and often leads to overselling of unproven and potentially dangerous treatments. Moreover, the involvement of a convicted fugitive as the operational mastermind raises serious questions about due diligence in corporate partnerships. Haier's initial denial and subsequent legal battle with Yu suggest that even large corporations struggle to control how their brand is used in this fragmented and opaque industry. Looking ahead, this scandal could prompt Chinese regulators to tighten rules on medical advertising, require more transparent ownership structures for medical institutions, and impose stricter penalties for false health claims. For consumers, the key takeaway is to be wary of miracle anti-aging treatments that lack scientific validation and to verify the credentials of medical providers before undergoing any procedure.

Frequently Asked Questions

Are "blood exchange" anti-aging treatments safe? No. The U.S. FDA has warned that such treatments have no proven anti-aging benefits and pose serious health risks, including infections and allergic reactions. There is no scientific consensus that they work.

Why is Haier involved in this? Haier has a minority stake (24%) in the hospital through its financial arm. Haier has publicly distanced itself from the controversial treatments and is suing Yu Wenhong for defamation, claiming she falsely used Haier's name to promote her business.

What should consumers consider before getting such treatments? Consumers should demand scientific evidence, check the credentials of the medical staff, and be cautious of high-pressure sales tactics. They should also verify that the treatments are approved by regulatory bodies like the NMPA (China's drug administration).

Source: https://www.163.com/money/article/KQLKU2UG002590RK.html